Advertisement Roller Compaction Advancements Leads Gerteis to their Most Successful Year - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
More info about

Roller Compaction Advancements Leads Gerteis to their Most Successful Year

Celebrating 25 years this year, Gerteis would like to thank all their customers for their continued support. Paul Gerteis CEO is dedicated to providing world leading technology for dry powder granulation for the pharmaceutical and healthcare industries. ‘We are focused on providing the best technology, and an internal culture of continued improvement, Gerteis work closely with their customers to optimise the process technology performance to allow the customer to focus on the product they are developing or manufacturing.’

The company remains privately owned, allowing it to be diligent at developing its technology and the staff employed, leading to success despite tough global market conditions. This determination has led to 2011 being their most successful year to date.

More and more customers are now seeing the benefits Gerteis technology brings and why the high standard of engineering and sophisticated control really matter, enabling higher quality pharmaceutical, food and chemical products to be developed and manufactured to a consistent and predictable high standard.

Gerteis offer the most versatile and advance roller compaction technology with the Pactor® range of machines, eliminating scale up, thus, dramatically reducing customer research and development costs. Gerteis have also launched a new range of high quality standardised compaction machines call the Polygran® range, these are for the simpler applications where customers seek Gerteis high quality of engineering and reliable process control, offering outstanding value.

Technology leadership has been an essential part of this success, the latest Mini Pactor® and Macro Pactor® offer advancements in system design, containment and clean in place. The high specification technology for OEB4 and OEB5 applications are the most advanced systems on the market, making potent drug development and manufacturing more practical, efficient and safer.

The Gerteis culture of working in close partnership with their customers pays off, Paul said, ‘We believe in supporting our customers, our value is often realised in the long term ownership of our equipment, we engineer our process machines to be as reliable as we possibly can, yet provide the best possible process control and consistency, this ultimately gives accurate and consistent granule quality to the point where we have significantly influence on tablet quality and even product effectiveness. We are able to process many many more products than our competitors with competing technologies.’

Celebrating 25 years and recording their best results in a though market reflects the efficiency advantages Gerteis technology offers. Substantial savings in new building costs, quality control costs, product versatility, energy costs and capital equipment costs compared to alternative technologies are all significant advantages with Gerteis.

Gerteis winning in partnership, celebrating 25 Years of Success.